Patents by Inventor Bradley P. Morgan

Bradley P. Morgan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11952381
    Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2A, R2B, R3, R4, and R5 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 4, 2022
    Date of Patent: April 9, 2024
    Assignee: CYTOKINETICS, INC.
    Inventors: Chihyuan Chuang, Bradley P. Morgan, Mark Vanderwal, Luke W. Ashcraft, Kevin Lau
  • Patent number: 11932631
    Abstract: Provided herein is a process for the preparation of (R)—N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide, intermediates thereof, and salts of the foregoing.
    Type: Grant
    Filed: August 2, 2022
    Date of Patent: March 19, 2024
    Assignee: CYTOKINETICS, INC.
    Inventors: Denise Andersen, Matthew Pfeiffer, Norma Tom, Bradley P. Morgan
  • Patent number: 11919909
    Abstract: Provided are compounds of Formula (I): or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R1, R2, R3, and R4 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods of using a compound of Formula (I), or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
    Type: Grant
    Filed: March 3, 2022
    Date of Patent: March 5, 2024
    Assignee: CYTOKINETICS, INC.
    Inventors: Bradley P. Morgan, Chihyuan Chuang, Luke W. Ashcraft, Justin Ho, Alfredo Garcia
  • Patent number: 11780826
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: February 15, 2022
    Date of Patent: October 10, 2023
    Assignees: AMGEN INC., CYTOKINETICS, INC.
    Inventors: Luke Ashcraft, Alessandro Boezio, John Butler, Aroop Chandra, Chihyuan Chuang, Scott E. Collibee, Mikkel Debenedetto, Vincent Dimassa, Russell Graceffa, Justin Malinowski, David Moebius, Bradley P. Morgan, Joshua Payette, Antonio Romero, David St. Jean, Jr., Richard Vargas, John Yeoman, Hanmo Zhang, Alan Cheng, Felix Gonzalez Lopez De Turiso, Michael Garrett Johnson
  • Publication number: 20230119665
    Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R1, R2, R3, G1, G2, and G3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 31, 2022
    Publication date: April 20, 2023
    Inventors: Chihyuan CHUANG, Bradley P. MORGAN, Mark VANDERWAL, Wenyue WANG, Luke W. ASHCRAFT
  • Publication number: 20230116972
    Abstract: Provided is a compound of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A, B, X1, X2, X3, and X4 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
    Type: Application
    Filed: July 11, 2022
    Publication date: April 20, 2023
    Inventors: Luke W. ASHCRAFT, Chihyuan CHUANG, Alfredo GARCIA, Bradley P. MORGAN, Bartlomiej Przemyslaw IWAN, Molly Eichel MERMIN
  • Publication number: 20230090256
    Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2A, R2B, R3, R4, and R5 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 4, 2022
    Publication date: March 23, 2023
    Inventors: Chihyuan CHUANG, Bradley P. MORGAN, Mark VANDERWAL, Luke W. ASHCRAFT, Kevin LAU
  • Publication number: 20230083960
    Abstract: Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.
    Type: Application
    Filed: November 5, 2021
    Publication date: March 16, 2023
    Inventors: Bradley P. MORGAN, Chris Evans, Pu-Ping Lu, Makoto Yamasaki, Wenyue Wang, Scott Collibee, Takuya Makino, Kazuyuki Tsuchiya, Toshio Kurosaki, Susumu Yamaki, Eriko Honjo, Yuka Koizumi, Naoto Katoh, Ryuichi Sekioka, Ikumi Kuriwaki, Denise Andersen
  • Publication number: 20230045450
    Abstract: Provided herein is a process for the preparation of (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide, intermediates thereof, and salts of the foregoing.
    Type: Application
    Filed: August 2, 2022
    Publication date: February 9, 2023
    Inventors: Denise ANDERSEN, Matthew PFEIFFER, Norma TOM, Bradley P. MORGAN
  • Publication number: 20230026651
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 20, 2022
    Publication date: January 26, 2023
    Inventors: Zhe YANG, Alex R. MUCI, Jeffrey WARRINGTON, Gustave BERGNES, Bradley P. MORGAN, Chihyuan CHUANG, Antonio ROMERO, Scott COLLIBEE, Xiangping QIAN, Pu-Ping LU
  • Publication number: 20220332708
    Abstract: The present disclosure relates to sulfonamide compounds and pharmaceutically acceptable salts thereof as cardiac sarcomere activators.
    Type: Application
    Filed: April 5, 2022
    Publication date: October 20, 2022
    Inventors: Jeffrey GARDINA, Aroop CHANDRA, Luke W. ASHCRAFT, Scott COLLIBEE, Chihyuan CHUANG, Alex MUCI - DECEASED, Bradley P. MORGAN, Antonio ROMERO, Michael JOHNSON, David MOEBIUS, Hanmo ZHANG, Felix GONZALEZ
  • Patent number: 11472796
    Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R1, R2, R3, G1, G2, and G3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: October 18, 2022
    Assignee: CYTOKINETICS, INC.
    Inventors: Chihyuan Chuang, Bradley P. Morgan, Mark Vanderwal, Wenyue Wang, Luke W. Ashcraft
  • Publication number: 20220315558
    Abstract: Provided herein are polymorphs of 1-(2-4((trans)-3-fluoro-1-(3-fluoropy-ridin-2-yl)cyclobutyl)methyl)amino)pyrimidin-5-yl)-1H-pyrrole-3-carboxamide (shown below), compositions thereof, methods of preparation thereof, and methods of their uses.
    Type: Application
    Filed: June 26, 2020
    Publication date: October 6, 2022
    Inventors: Bradley P. MORGAN, Matthew W. PETERSON
  • Publication number: 20220306642
    Abstract: Provided are compounds of Formula (I): or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R1, R2, R3, and R4 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods of using a compound of Formula (I), or stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.
    Type: Application
    Filed: March 3, 2022
    Publication date: September 29, 2022
    Inventors: Bradley P. MORGAN, Chihyuan CHUANG, Luke W. ASHCRAFT, Justin HO, Alfredo GARCIA
  • Publication number: 20220281850
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Application
    Filed: February 15, 2022
    Publication date: September 8, 2022
    Inventors: Luke ASHCRAFT, Alessandro BOEZIO, John BUTLER, Aroop CHANDRA, Chihyuan CHUANG, Scott E. COLLIBEE, Mikkel DEBENEDETTO, Vincent DIMASSA, Russell GRACEFFA, Justin MALINOWSKI, David MOEBIUS, Bradley P. MORGAN, Joshua PAYETTE, Antonio ROMERO, David ST. JEAN, JR., Richard VARGAS, John YEOMAN, Hanmo ZHANG, Alan CHENG, Felix GONZALEZ LOPEZ DE TURISO, Michael Garrett JOHNSON
  • Patent number: 11414424
    Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2A, R2B, R3, R4, and R5 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: August 16, 2022
    Assignee: CYTOKINETICS, INC.
    Inventors: Chihyuan Chuang, Bradley P. Morgan, Mark Vanderwal, Luke W. Ashcraft, Kevin Lau
  • Patent number: 11369565
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and mare as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 28, 2020
    Date of Patent: June 28, 2022
    Assignee: CYTOKINETICS, INC.
    Inventors: Zhe Yang, Alex R. Muci, Jeffrey Warrington, Gustave Bergnes, Bradley P. Morgan, Chihyuan Chuang, Antonio Romero, Scott Collibee, Xiangping Qian, Pu-Ping Lu
  • Publication number: 20210276991
    Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, Y1, Y2, L1, and G1 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 25, 2019
    Publication date: September 9, 2021
    Inventors: Bradley P. MORGAN, Mark VANDERWAL, Chihyuan CHUANG
  • Publication number: 20210253563
    Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, and R3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 25, 2019
    Publication date: August 19, 2021
    Inventors: Bradley P. MORGAN, Chihyuan CHUANG
  • Publication number: 20210147399
    Abstract: Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R1, R2, R3, G1, G2, and G3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 4, 2020
    Publication date: May 20, 2021
    Inventors: Chihyuan CHUANG, Bradley P. MORGAN, Mark VANDERWAL, Wenyue WANG, Luke W. ASHCRAFT